Nursing Pharmacology: Immunology Immmunopharmacology

MENU I: Immunopharmacology Topics
Introduction Innate Immune System Adaptive Immune System Characteristics Effectors of Humoral Immunity Effectors of Cell-Mediated Immunity Specific Immunity: Requirements Lymphocyte Selection Subsets of T helper lymphocytes TH1 Cell-mediated Immunity TH2 Humoral Immunity T helper lymphocytes: Mutual Regulation Cytotoxic Consequences of Immune System Activation Activated cytotoxic T Cells MHC molecules NK cells: main precursor of lymphokine activated killer (LAK) cells B lymphocytes: Humoral Immunity Steps following Antigen binding to B-cell membrane immunoglobulin (IgM or IgD) Abnormal Immune Responses Hypersensitivity Autoimmunity Immunodeficiency Hypersensitivity Immediate hypersensitivity TypeI Characteristics Consequences Type II Characteristics Occurences Consequences Newborn hemolytic disease Prevention Drug-Induced Type III Characteristics Delayed Hypersensitivity Macrophage/Neutrophil Recruitment Autoimmunity Introduction Clinical Pathologic Consequences Rheumatoid arthritis Systemic Lupus Erythrematosis Insulin-Dependent Diabetes Mellitus Possible Explanations for Autoimmune Disease Immunodeficiency Diseases Overview Congenital Immunodeficiency X-linked agammaglobulinemia DiGeorge's syndrome Severe Combined Immunodeficiency Disease (SCID) ADA deficiency Acquired immunodeficiency: AIDS HIV Immunocompetency Testing Immunosuppressive Therapy & Cancer Chemotherapy	Immunosuppressive Drugs Corticosteroids Lympholytic activity Effects on inflammatory mediators Effects on neutrophils/monocytes leukocyte distribution Cytokine Effects Clinical Uses Autoimmune Disorders Adverse Effects Cyclosporine Pharmacokinetics/Pharmacodynamics Site of Action Inhibition of Gene Transcription Graft-vs-Host Syndrome Adverse Effects/Toxicities Clinical Use Immunosuppression Monotherapy Tacrolimus (FK 506) Mechanism of Action Adverse/Toxic Effects Interferons Families Type I Interferon Effects Clinical Uses New Immunosuppressive Agents Mycophenolate mofetil Possible Clinical Uses Related Drugs of Interest 15-desoxyspergualin Antimonocytic Effects Clinical Uses Sirolimus Mechanism of Action Possible Clinical Uses Thalidomide Clinical Uses Immunosuppressive Cytotoxic Drugs Azathioprine Chemistry Primary Use Pharmacokinetics/pharmacodynamics Mechanism of Immunosuppression Clinical Use Toxicities Cyclophosphamide Clinical Uses Autoimmune Disorders Adverse effects Vincristine Clinical Use Adverse Effects Vinblastine Clinical Use Adverse Effects Methotrexate (MTX) Mechanism of Action Adverse Effects Clinical Uses Dactinomycin Mechanism of Action Clinical Use Adverse Effects NEXT MENU

Immunopharmacology
Introduction-- Immune System Defenses against antigenic insults: Innate immune system Adaptive immune system Innate Immune System Physical (skin) Biochemical (e.g. complement, lysozyme) Cellular (e.g. macrophages, neutrophils) When the barrier is disrupted, bacterial destruction may occur by: Lysozyme enzyme activity: ® peptidoglycan cell wall component cleavage; also: split products from complement activation complement components: enhance macrophage and neutrophil phagocytosis by: Acting as opsonins (C3b) Attracting immunocytes to inflammatory sites (C3a, C5a) Promoting bacterial lysis -- membrane attack complex generation Adaptive Immune System The adaptive immune system comes into play if the innate immune system has not managed the infection adequately. Characteristics of the adaptive immune system: Specific responses to a variety managements Discriminate between foreign ("nonself") and "self", i.e. host antigens Exhibits "memory"; initiates an aggressive response to previously encountered antigen Effectors of humoral immunity: antibodies Effectors of cell mediated immunity: activated lymphocytes Specific Immunity:-- requirements Antigen presenting cells (APCs) Langerhans cells B lymphocytes Dendritic cells Macrophages APCs digest antigens (enzymatically) producing peptides that: Interact with T cell lymphocyte receptors (TCR) in association with class I and class II major histocompatibility complex proteins (MHC proteins) T cell lymphocyte activation-- additional molecular dependencies: CD₄ on helper T cells CD₈ on cytotoxic T cells LFA-1(lymphocyte functional antigen) and CD₂ on both helper and cytotoxic T cells Co-stimulatory molecules (B7.1 and B7.2) by cognate receptors on APCs Lymphocyte selection: Thymic lymphocyte that bind to "self"-- eliminated by apotosis (negative selection) Thymic lymphocytes that respond to foreign antigens in the presence of "self" MHC: retained (positive selection) and distributed to peripheral sites, available for later activation (after interacting with MHC-presented peptides): Lymph node Spleen Peripheral blood Musosa-associated lymphoid tissue Subsets of T helper lymphocytes--discrimination based on cytokine secretion, after activation TH1: Cell-mediated Immunity Produces interferon-g (IFNg) Produces interleukin-2 (IL-2) Produces tumor necrosis factor-b (TNFb) Induces cell-mediated immunity by activation of: Cytotoxic T cells (CTL) Natural killer (NK) cells Macrophages TH2: Humoral Immunity Produces (interleukins) IL-4, IL-5, IL-6 which in turn causes: B-cell proliferation Differentiation into antibody secreting plasma cells T helper lymphocytes --mutual regulation: TH2 cells produce IL-10: inhibits TH1 cytokine production (down-regulates MHC expression by APCs) TH1 interferon-g: inhibits TH2 cell proliferation Other down-regulation/suppression factors (in some tissues) Transforming growth factor-b (TGF-b) Down-regulates lymphocyte proliferation prostaglandin E2: down-regulates immune response T helper lymphocytes: phenotype selection based on antigenic challenge extracellular bacteria: TH2 cytokine release intracellular organisms (e.g. Mycobacterium): TH1 cytokine release Cytotoxic Consequences of Immune System Activation Activated cytotoxic T cells (recognize processed peptides presented by virus-infected cells/tumor cells) Induce target cell death by: Perforin Lytic granule enzymes ("granzymes") Fas-Fas ligand (Fas-Fasl) apotosis pathway Nitric oxide (may be released): inhibits cell enzymes Viral Antigen Presentation (by virus-infected cells) Nonapeptide fragments in the group of class 1 MHC molecules MHC molecules Class I MHC molecules: presenting fragments of cellular antigens (virus/tumor antigens)--after Golgi apparatus processing Class II MHC molecules: presenting antigen fragments from: Internalized/enzymatically digested foreign antigens *Natural Killer Cells: (NK): (CD16+, CD56+, CD57+)--possible role in tumor rejection/viral immunity; in vivo* role uncertain NK cells: large granular lymphocytes Azurophilic cytoplasmic granules Surface immunoglobulin negative FC receptor-positive Probably separate lymphoid cell lineage NK cells: main precursor of lymphokine activated killer (LAK.)cells LAK cells: Stimulated by IL-2 (high concentration) Referred to as (promiscuous killers) because: Kill across MHC barriers Kill target cells not expressing MHC B lymphocytes: Humoral Immunity Self-reactive B lymphocytes clonally deleted in the bone marrow B-cell clones specific for foreign antigens -- retained/expanded B-cell specificities due to:** Immunoglobulin gene rearrangement These determinations occur prior to antigen exposure Antigen specificity: T cells -- genetically determined; derive from T-cell receptors Sequence following Antigen binding to B-cell membrane immunoglobulin (IgM or IgD): Antigen endocytosed, processed, presented to CD4+ T helper cells T helper cells then stimulated to produce IL-4 and IL-5 Interleukins IL-4 and IL-5 stimulate: B cells proliferation B-cell differentiation into memory B cells Antibody secreting plasma cells Primary antibody response: IgM-class immunoglobulins Later antigenic stimulation ® "booster" response associated with: Class switching (isotype switching) to produce IgG, IgA, IgD antibodies with various effector functions Evolution over time: Increased affinity; more efficient antigen buying Antibodies act is opsonins to enhance phagocytosis, cellular cytotoxicity, and by activating complement ® inflammatory response ® bacterial lysis